Eton Pharmaceuticals (ETON) Earnings Analysis
Eton Pharmaceuticals (ETON) next reports earnings on 2026-08-06, consensus EPS 0.13 USD. Last quarter (2026-05-14) it missed with EPS 0.05 USD vs 0.1 USD est (-50%). It has beaten estimates in 1/6 recent quarters (17%). Trailing P/E -852.84.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ETON next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 0.13 USD |
| Revenue estimate | 0.03B |
ETON earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-14 | 0.05 USD | 0.1 USD | -50% | Miss |
| 2026-03-19 | 0.05 USD | 0.12 USD | -58.3% | Miss |
| 2025-11-06 | -0.07 USD | 0.16 USD | -143.8% | Miss |
| 2025-08-07 | -0.1 USD | -0.01 USD | -900% | Miss |
| 2025-03-18 | -0.02 USD | -0.02 USD | 0% | Beat |
| 2024-08-08 | -0.12 USD | -0.07 USD | -71.4% | Miss |
Beat rate: 1/6 (17%) over reported quarters with consensus data.
ETON valuation and analyst view
| Trailing P/E | -852.84 |
|---|---|
| Trailing EPS | -0.05406 USD |
| Price / book | 38.84 |
| Dividend yield | 0.00% |
| Market cap | 1.19B |
| Analyst consensus | Buy (6 buy / 0 hold / 0 sell) |
| Avg price target | 58.5 USD |
Related research pages
Frequently asked questions
When is Eton Pharmaceuticals (ETON)'s next earnings date?
Eton Pharmaceuticals is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 0.13 USD and revenue estimate of 0.03B.
Did ETON beat earnings last quarter?
In its 2026-05-14 report, ETON posted EPS of 0.05 USD versus a 0.1 USD estimate — a miss of 50%.
What is ETON's earnings track record?
Over the last 6 reported quarters with consensus data, ETON beat estimates 1 times (17%).
What is ETON's current P/E ratio and EPS?
ETON trades at a trailing P/E of -852.84 on trailing EPS of -0.05405900678028221 USD.
What do analysts rate ETON?
Analyst consensus is "Buy" across 6 ratings (0 strong buy, 6 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 58.5 USD.